Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors according to each SARM’s chemical structure. Therefore, SARMs bring about anabolic cellular activity while avoiding many of the unwanted effects of now available anabolic steroids. SARMs have already been studied from the management of breast cancer and cachexia and possess been utilized as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs.
Aim
To provide the backdrop, mechanisms, current and potential clinical applications, in addition to risks and benefits of SARMs.
Methods
A literature review was performed in MEDLINE while using terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both preliminary research and studies were included.
Main Outcome Measure
To complete a review of peer-reviewed literature.
Results
Although there are currently no U.S. Drug and food Agency-approved indications for SARMs, investigators are exploring the potential uses of these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability having a paucity of drug interactions. Early clinical tests have demonstrated potential uses of SARMs in the treating cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancers, with good success.
Conclusion
SARMs have several possible clinical applications, with promise for the safe use within the treatment of cachexia, BPH, hypogonadism, cancer of the breast, and prostate type of cancer.
To learn more about Sarms for sale view this web site.